The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Exact Sciences Corp. announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

KU Cancer Center deploys new mobile cancer screening bus

The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account